Facilitating Global Innovation & Partnering

Press Releases

Poorly Soluble and Poorly Permeable Drugs valued at $145 billion represent significant reformulation and market opportunities Download PDF

July 1, 2014

Poor bioavailability is a major reason for compounds to fail in preclinical development. Technology Catalysts International (TCI) has compiled and analyzed technical and market information pertaining to the delivery of poorly water soluble or poorly permeable pharmaceutical compounds.

Read more: Delivery of Poorly Soluble or Poorly Permeable Drugs – 7th Edition